Omecamtiv mecarbil (OM) is a small molecule proved to enhance the function of the beta-myosin motor and presently used for the treatment of heart failure. Despite the positive outcomes of clinical trials, the mechanistic basis of its action is controversial and little is known of its functional impact in human cardiac sarcomeres. Here myofibrils from human donor left ventricle (frozen samples) have been used to study the effects of μmolar [OM] on isometric force in relaxing conditions (pCa 9) and at maximal (pCa 4.5) or half-maximal (pCa 5.75) calcium activation, both in control conditions (15°C, equimolar DMSO, contaminant [Pi] ∼ 170µM) or in presence of 5 mM [Pi]. In all conditions tested, OM increased isometric force with a complex dose-dependent effect peaking (about 40% increase) at 0.5 µM and never decreasing below control values. As already reported in human cardiac muscle (Swenson et al. 2017), OM strongly depressed the kinetics of force development up to 90% at 10 µM OM. Of note, OM was found to decrease the inhibition of force operated by Pi, in agreement with observations in rabbit slow-muscle (Governali et al. 2020), but the effect was modest and occurred at low (1-2 mM) [Pi]. At pCa 9 OM induced calcium-independent force development which approached the level of calcium activated tension at 10 µM OM. The kinetics of the calcium-independent force development at pCa 9 was very slow and dose-independent. The results support a role of OM in operating a complex perturbation of the thin/thick filament regulatory state as a result of its binding to myosin allosteric sites coupled to Pi release that favours the formation of strongly actin-bound motors. SilicoFCM EU H2020 grant agreement n. 777204.
Read full abstract